Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunological complications in multiple sclerosis patients receiving interferon.

G P Rice, E L Woelfel, P J Talbot

    Annals of Neurology
    |October 1, 1985
    PubMed
    Summary

    Human alpha interferon (IFN) treatment for multiple sclerosis activated immune cells and increased antibody responses to contaminants. Some patients developed immune complex disease symptoms, indicating significant immune system effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

    The pharmacogenomics journal·2009
    Same author

    Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
    Same author

    Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).

    International journal of obesity (2005)·2005
    Same author

    Interferon in relapsing-remitting multiple sclerosis.

    The Cochrane database of systematic reviews·2001
    Same author

    Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.

    AJNR. American journal of neuroradiology·2001
    Same author

    The effect of cladribine on T(1) 'black hole' changes in progressive MS.

    Journal of the neurological sciences·2000

    Area of Science:

    • Immunology
    • Neuroimmunology
    • Pharmacology

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Interferons are cytokines with immunomodulatory properties, investigated for MS treatment.
    • Previous studies suggested potential benefits of interferon therapy in MS.

    Purpose of the Study:

    • To evaluate the efficacy and immunological effects of human alpha interferon (IFN) in multiple sclerosis (MS) patients.
    • To monitor specific immune system functions during IFN treatment.
    • To identify potential adverse immune-related events associated with IFN therapy.

    Main Methods:

    • Prospective, placebo-controlled study design.
    • Monitoring of immunological functions, including natural killer cell activity.

    Related Experiment Videos

  • Measurement of serum immunoglobulin and cerebrospinal fluid IgG ratios.
  • Assay for antibody titers against a protein contaminant in the IFN preparation.
  • Quantification of C1q- and Raji-binding immune complexes.

    • Main Results:

    • IFN treatment activated natural killer cells in vivo.
    • Elevated serum immunoglobulin and cerebrospinal fluid IgG ratios were observed.
    • All patients receiving IFN developed antibodies to a 27-kDa protein contaminant.
    • Six of 12 patients showed elevated immune complexes (C1q- and Raji-binding).
    • Some patients exhibited symptoms suggestive of immune complex disease.

    Conclusions:

    • Human alpha interferon (IFN) exerts significant immunomodulatory effects in multiple sclerosis patients.
    • The development of antibodies to IFN contaminants can lead to immune complex formation.
    • IFN therapy may be associated with immune complex disease in some individuals.
    • Further investigation into the immunogenicity of IFN preparations is warranted.